Johnson & Johnson and Varian Medical Systems are in line for exits after cancer therapy developer Fusion filed for a $100m initial public offering.
Fusion Pharmaceuticals, a Canada-based cancer radiopharmaceuticals developer that counts medical technology provider Varian Medical Systems and pharmaceutical group Johnson & Johnson as investors, has filed for a $100m initial public offering.
Founded in 2014, Fusion is developing targeted alpha therapeutics, a type of cancer treatment that relies on equipping molecules such as antibodies with radioactive particles – called alpha emitting medical isotopes – to kill cancer cells.
Alpha particles can only travel a short distance, making it possible to localise…
